Botox Cosmetic für Kieferlinie-Behandlung in China zugelassen Von Investing.com

IRVINE, Calif. – Allergan Aesthetics, a subsidiary of AbbVie (NYSE: NYSE: ), has approved Botox Cosmetic (OnabotulinumtoxinA) for the treatment of Masseter Muscle Prominence (MMP) in China. MMP, a product that is one of the largest, quadrilateral kyferal lines that have enlarged skin, can now be treated with Botox Cosmetic. This Botox Cosmetic is the first neurotoxin to be used by the Chinese national medical production for this indication.

The study is conducted in a phase 3 clinical trial, the study, the Botox cosmetics in the place of a placebo with a size of 5.2 mm, is an extension of the general coverage, which lasts very 6-9 months. The study reports are very positive about patient reports about bad reports about social interactions, attractions and self-study. The side effects were mild to moderate and provided a Sicherheitsprofil of the products.

This development has been developed, the MMP is a very aesthetic anliegen, among the Asian population, which no invasive treatment possibilities were limited. Professor Sun Jiaming, one of the leading clinical studies, has investigated the treatment of Botox cosmetics and an effective treatment of einzeldosis, which can make all the medical studies and the patient can get a slimmer and a clearer clinical picture.

Allergan Aesthetics is pursuing sales of Botox Cosmetic for MMP in other global markets. The U.S. Food and Drug Administration’s review does not apply to MMP zugelassen, which further advances the global Research and Development of the Company to this Application.

The announcement follows at a time when Botox Cosmetic with over 150 million world-wide shared fluids continues to be a trusted name in aesthetic medicine. It is a fact that trade in China is one of the most invasive aesthetic operations. This focuses on a press conference of Allergan Aesthetics.

InvestingPro Introduction

As AbbVie (NYSE: ABBV) celebrates the approval of Botox Cosmetic for MMP in China, investors are taking notice of the market and financing their companies’ healthcare. AbbVie’s commitment to the production of products comes in a long time with strong financial knowledge, according to new data from InvestingPro. The market capitalization of the U.S. economy was $352.12 billion, reflecting the investors’ turnover in their business model and the broader mirror of the Wachstum.

One of the most important InvestingPro tips for AbbVie is a discontinued dividend investment strategy, with a 12-year steepening. As the stress of the internal economies eases, stable cash flows are generated and their involvement increases, while the operations will continue. Since AbbVie’s Net Income has done its best during those years, the potential for a discontinued financial business and lagging profitability was there.

InvestingPro Data says that AbbVies Aktie is trading with a high profit multiplier with a KGV of 66.03. When the end of the first Blick after a premium-bewertung in Australia is reached, it is important that the companies’ Wachstum-sauszichten and their dominant position in the Biotechnology industry reach their goal. By analysts in the profit forecast for the coming period after the correction, Optimism herrstüglich AbbVies future performance.

For investors who often make such an investment, InvestingPro tips and tips can use AbbVie the Aspect with a small pre-volatile value of the Enternehmens and their Position as a profitable Actor in the Biotechnology sector. For this and other investment strategies, you can get more tips on the InvestingPro platform at https://www.investing.com/pro/ABBV.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.